MYL
Robert Coury - Non-Executive Chairman of the Board of Mylan N.V.

Person placeholder

Robert Coury

Non-Executive Chairman of the Board since 2016

Total compensation: $97,600,600
Age: 56

Robert J. Coury is Non-Executive Chairman of the Board of the Company. Robert J. Coury is the Chairman of Mylan N.V. Under his visionary leadership, Mylan has transformed from the third largest generics pharmaceutical company in the U.S. into one of the largest pharmaceutical companies in the world in terms of revenue, earning spots in both the S&P 500 and, prior to the Company’s reincorporation outside of the U.S. in 2015, the Fortune 500. Mr. Coury was first elected to the Mylan Board in February 2002, having served since 1995 as a strategic advisor to the Company. He became the Mylan Board’s Vice Chairman shortly after his election and served as CEO from September 2002 until January 2012, and as Executive Chairman from 2012 until he became Chairman as a director who is not an employee of the Company or Mylan Inc. (a “Non-Employee Director”, with all such directors being the “Non-Employee Directors”) in June 2016. Since 2007, Mr. Coury has led the Company through a series of transactions totaling approximately $25 billion, which transformed Mylan into a global powerhouse within the highly competitive pharmaceutical industry, with a global workforce of over 35,000 and products sold in more than 165 countries. In 2007, Mylan purchased India-based Matrix Laboratories Limited, a major producer of active pharmaceutical ingredients, and the generics and specialty pharmaceuticals business of Europe-based Merck KGaA. Subsequent acquisitions under Mr. Coury’s leadership further expanded the Company into new therapeutic categories and greatly enhanced its geographic and commercial footprint. In 2010, Mylan acquired Bioniche Pharma, a global injectables business in Ireland; in 2013, Mylan acquired India-based Agila Specialties, a global injectables company; and in 2015, Mylan acquired the EPD Business and Famy Care Ltd.’s women’s healthcare businesses.

About Mylan N.V.

Mylan N.V. logo

Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms. The company also manufactures and sells a portfolio of injectable products across various therapeutic areas, including respiratory and allergy, infectious disease, cardiovascular, oncology, and central nervous system and anesthesia; active pharmaceutical ingredients; antiretroviral therapy products for people living with HIV/AIDS; and products in the therapeutic categories, such as hepatology and critical care. In addition, it provides EpiPen Auto-Injector, which is used to treat severe allergic reactions; Perforomist Inhalation Solution, a formoterol fumarate inhalation solution for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder patients; ULTIVA, an analgesic agent used during the induction and maintenance of general anesthesia for inpatient and outpatient procedures; and Dymista, which is used for the treatment of seasonal allergic rhinitis. The company markets its products to wholesalers, distributors, retail pharmacy chains, mail order pharmacies, and group purchasing organizations; and independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit managers. The company was formerly known as New Moon B.V. Mylan N.V. was founded in 1961 and is based in Hatfield, the United Kingdom.

  • Mylan N.V., Building 4, Hatfield AL10 9UL, United Kingdom
  • mylan.com
  • 44 17 0785 3000
Messenger